Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute, discusses the Stand Up to Cancer-Melanoma Research Alliance Dream Team.
Jeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute (TGen), discusses the Stand Up to Cancer (SU2C)-Melanoma Research Alliance (MRA) Dream Team.
The SU2C-MRA Dream Team focuses on investigating the utility of personalized targeted therapies and therapy identification in specific subgroups of patients with melanoma, such as BRAF wild-type. At TGen, researchers primarily focus on genomic information, looking at both hereditary information and genetic changes in cancer cells, to examine differences and impact clinical decision-making, Trent explains.
The SU2C-MRA Dream Team is three years into developing approaches, infrastructure, technologies, and reporting associated with FDA regulatory approvals. Thus far, Dream Team researchers have examined approximately seven patients out of more than 100 enrolled in the trial, Trent says.